GlassScriptPhysician profile
Kerri B Robbins
NPI 1255602405
$5,676.46
in general payments reported to CMS, 2019-2025
22 companies · $2,146 in 2025
The $2,146 reported for 2025 was more than what 95% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $158 · 2022: $837 · 2023: $1,241 · 2024: $1,295 · 2025: $2,146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,682 · Travel and Lodging: $999.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,682.08 |
| Travel and Lodging | $999.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $1,401.29 | 2025 | Epi-Sense Guided Coagulation System With Visitrax, Synergy Ablation System |
| Amgen INC. | $781.96 | 2022-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $663.74 | 2021-2025 | Lifevest |
| Abbott Laboratories | $504.44 | 2022-2024 | Epic, Cardiomems |
| Pfizer INC. | $327.74 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $279.42 | 2022-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $238.46 | 2025 | |
| Abiomed | $230.38 | 2023-2024 | Impella |
| Astrazeneca Pharmaceuticals LP | $209.85 | 2021-2024 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $201.96 | 2021-2023 | Camzyos |
| Heartflow, INC. | $182.06 | 2023 | Ffrct |
| Novo Nordisk INC | $113.25 | 2024 | Wegovy, Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.50 | 2021-2023 | Jardiance |
| Irhythm Technologies, INC. | $105.46 | 2024 | Zio Xt Patch, Zio Monitor |
| Actelion Pharmaceuticals US, INC. | $99.22 | 2024 | Opsumit, Uptravi |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $57.03 | 2024-2025 | |
| Kiniksa Pharmaceuticals International, Plc | $40.99 | 2024 | Arcalyst |
| Sanofi-Aventis U.S. LLC | $32.87 | 2023-2024 | |
| Lexicon Pharmaceuticals, INC. | $30.99 | 2023 | Inpefa |
| Recor Medical INC | $25.54 | 2024 | Paradise Renal Denervation System |
| Abbvie INC. | $20.71 | 2025 | |
| Haemonetics Corporation | $17.60 | 2023 | Teg6s Hemostasis System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kerri Robbins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.